SK283591B6 - Spôsob prípravy tolterodínu a medziprodukt - Google Patents

Spôsob prípravy tolterodínu a medziprodukt Download PDF

Info

Publication number
SK283591B6
SK283591B6 SK815-99A SK81599A SK283591B6 SK 283591 B6 SK283591 B6 SK 283591B6 SK 81599 A SK81599 A SK 81599A SK 283591 B6 SK283591 B6 SK 283591B6
Authority
SK
Slovakia
Prior art keywords
tolterodine
formula
added
methanol
methyl
Prior art date
Application number
SK815-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK81599A3 (en
Inventor
James R. Gage
John E. Cabaj
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of SK81599A3 publication Critical patent/SK81599A3/sk
Publication of SK283591B6 publication Critical patent/SK283591B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
SK815-99A 1996-12-31 1997-12-18 Spôsob prípravy tolterodínu a medziprodukt SK283591B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3396196P 1996-12-31 1996-12-31
PCT/US1997/022521 WO1998029402A1 (en) 1996-12-31 1997-12-18 Process to prepare tolterodine

Publications (2)

Publication Number Publication Date
SK81599A3 SK81599A3 (en) 1999-12-10
SK283591B6 true SK283591B6 (sk) 2003-10-07

Family

ID=21873473

Family Applications (1)

Application Number Title Priority Date Filing Date
SK815-99A SK283591B6 (sk) 1996-12-31 1997-12-18 Spôsob prípravy tolterodínu a medziprodukt

Country Status (23)

Country Link
US (1) US5922914A (ja)
EP (1) EP0960109B1 (ja)
JP (1) JP4199310B2 (ja)
KR (2) KR20000057548A (ja)
CN (1) CN1151141C (ja)
AT (1) ATE226949T1 (ja)
AU (1) AU717985B2 (ja)
CA (1) CA2273789C (ja)
CZ (1) CZ295477B6 (ja)
DE (1) DE69716767T2 (ja)
DK (1) DK0960109T3 (ja)
ES (1) ES2186018T3 (ja)
FI (1) FI991477A0 (ja)
HK (1) HK1023566A1 (ja)
HU (1) HUP0000527A3 (ja)
NO (1) NO317158B1 (ja)
NZ (1) NZ336533A (ja)
PL (1) PL191603B1 (ja)
PT (1) PT960109E (ja)
RU (1) RU2176246C2 (ja)
SI (1) SI0960109T1 (ja)
SK (1) SK283591B6 (ja)
WO (1) WO1998029402A1 (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE60035232T2 (de) * 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
IN191835B (ja) * 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
WO2003035599A1 (en) * 2001-10-26 2003-05-01 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
BR0313714A (pt) * 2002-08-28 2005-06-28 Pharmacia Corp Composição oral de tolterodina lìquida
EP2177511A2 (en) 2002-12-10 2010-04-21 Ranbaxy Laboratories Limited Process for preparing 3,6-disubstituted azabicyclo derivatives
DE60225195T2 (de) 2002-12-23 2009-02-26 Ranbaxy Laboratories, Ltd. Flavaxat-derivate als muscarin-rezeptor antagonisten
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2004218178A1 (en) * 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited 3,3-diarylpropylamine derivatives and processes for isolation thereof
AU2003304037A1 (en) * 2003-04-08 2004-11-01 Hetero Drugs Limited Novel polymorphs of tolterodine tartrate
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7592359B2 (en) 2003-04-10 2009-09-22 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
ITMI20031354A1 (it) * 2003-07-02 2005-01-03 Istituto Di Chimica Biomolecolare D El Cnr Sezione Sintesis enantioselettiva di composti enantiomericamente arricchiti.
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (en) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
ITMI20041920A1 (it) * 2004-10-11 2005-01-11 Chemi Spa Processo per la preparazione di n, n-diisopropil-3-2-idrossi-5-metilfenil-3-fenil-propabammina
US7355077B2 (en) * 2004-10-28 2008-04-08 Dr. Reddy's Laboratories Limited Process for preparing tolterodine
JP4513535B2 (ja) * 2004-12-03 2010-07-28 住友化学株式会社 トルテロジンの製造方法
JP2007527923A (ja) * 2005-01-10 2007-10-04 テバ ファーマシューティカル インダストリーズ リミティド トルテロジンタルトレートの調製方法
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
ES2268987B1 (es) 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
KR100686351B1 (ko) * 2006-01-12 2007-02-22 주식회사 카이로제닉스 톨테로딘 라세미체의 제조방법
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
MX2008012976A (es) * 2006-05-24 2008-10-17 Pfizer Ltd Procedimiento para la produccion de derivados de benzopiran-2-ol.
US7268257B1 (en) 2006-05-31 2007-09-11 Sumitomo Chemical Company, Limited Process for producing tolterodine
CZ302585B6 (cs) * 2007-02-26 2011-07-20 Zentiva, A. S. Krystalická sul 2-[(1R)-3-[bis(1-methylethyl)amino]-1-fenylpropyl]-4-methylfenolu s kyselinou (2R,3R)-2,3-dihydroxybutandiovou
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
KR101188333B1 (ko) 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
WO2010092500A2 (en) 2009-02-12 2010-08-19 Alembic Limited A process for the preparation of tolterodine tartrate
EP2398765A1 (en) * 2009-02-17 2011-12-28 Pharmathen S.A. Improved process for the preparation of (r)-2-(3-diisopropylamino)-1-phenylpropyl)-4methylphenol and salts thereof
US8729056B2 (en) 2010-03-31 2014-05-20 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of hand-foot syndrome
EP2476665A1 (en) 2011-01-17 2012-07-18 Cambrex Profarmaco Milano S.r.l. Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate
WO2012098044A1 (en) 2011-01-17 2012-07-26 Cambrex Profarmaco Milano S.R.L. Process for the preparation of n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)- 3-phenyl propylamine and its salts starting from a novel intermediate
CN102516098B (zh) * 2011-12-09 2014-06-18 北京联本医药化学技术有限公司 酒石酸托特罗定制备方法
CN103044274B (zh) * 2012-11-29 2014-10-22 珠海保税区丽珠合成制药有限公司 一种无溶剂合成酒石酸托特罗定的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
CN110229072B (zh) * 2019-06-25 2022-04-08 中国药科大学 一种托特罗定及其对映体的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
DE69716767D1 (de) 2002-12-05
SK81599A3 (en) 1999-12-10
PL191603B1 (pl) 2006-06-30
ES2186018T3 (es) 2003-05-01
CZ227299A3 (cs) 1999-11-17
US5922914A (en) 1999-07-13
HK1023566A1 (en) 2000-09-15
NZ336533A (en) 2000-05-26
WO1998029402A1 (en) 1998-07-09
NO317158B1 (no) 2004-08-30
PT960109E (pt) 2003-03-31
DE69716767T2 (de) 2003-06-12
KR20000069771A (ko) 2000-11-25
KR20000057548A (ko) 2000-09-25
EP0960109A1 (en) 1999-12-01
KR100463614B1 (ko) 2004-12-29
CZ295477B6 (cs) 2005-08-17
PL334375A1 (en) 2000-02-28
FI991477A (fi) 1999-06-29
CA2273789A1 (en) 1998-07-09
NO993247D0 (no) 1999-06-29
JP4199310B2 (ja) 2008-12-17
AU5956998A (en) 1998-07-31
NO993247L (no) 1999-08-09
RU2176246C2 (ru) 2001-11-27
HUP0000527A3 (en) 2001-12-28
ATE226949T1 (de) 2002-11-15
AU717985B2 (en) 2000-04-06
DK0960109T3 (da) 2002-11-25
CA2273789C (en) 2006-06-06
CN1151141C (zh) 2004-05-26
JP2001507691A (ja) 2001-06-12
CN1238768A (zh) 1999-12-15
FI991477A0 (fi) 1999-06-29
SI0960109T1 (en) 2003-04-30
HUP0000527A2 (hu) 2001-11-28
EP0960109B1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
SK283591B6 (sk) Spôsob prípravy tolterodínu a medziprodukt
US5434304A (en) Process for preparing formoterol and related compounds
EP0550612B1 (en) New process for preparing formoterol and related compounds
SK128494A3 (en) Method of production of indanylamine compounds
EP1289929A1 (de) Verkürzte synthese von 3,3-diarylpropylamin-derivaten
CN101466695B (zh) 新手性中间体、其制备方法及其在托特罗定、非索罗定或其活性代谢物制备中的用途
EP0538080A1 (fr) Dérivés de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique
US8247559B2 (en) Process for preparing an intermediate to mu opioid receptor antagonists
JP2005507900A (ja) シタロプラムの製造方法
JP2016523832A (ja) アルホルモテロールまたはその塩の調製のためのプロセス
SU1240362A3 (ru) Способ получени производных гидантоина
WO2007069050A2 (en) Processes for the preparation of alfuzosin
WO2010126138A1 (ja) ３環性ベンゾピラン化合物の新規な結晶形態及びその製造方法
CN113754643A (zh) 苯并吡喃衍生物的精制方法、其晶型及所述晶型的制备方法
HU195204B (en) Process for the diastereoselective reduction of 3-amino-1-benzoxepin-5/2/+/-ones
FR2555580A1 (fr) Nouveaux composes azabicycliques, procede pour les preparer et medicaments les contenant
MXPA99006147A (en) Process to prepare tolterodine
WO2024015861A1 (en) Methods of preparation of heterocyclic compounds
BE1004471A3 (fr) Nouveaux derives diester d'octahydro-indolo-[2,3-a]-tetrahydropyranyl [2,3-c] quinolizine racemiques et optiquement actifs et procede pour les preparer.
EP1486492A2 (en) A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20111218